(Press-News.org) Today, the U.S. Department of Energy (DOE) announced the issuance of a Request for Proposals (RFPs) for the competitive selection of a management and operating contractor for the Thomas Jefferson National Accelerator Facility (TJNAF).
TJNAF is a DOE national laboratory and DOE-sponsored Federally Funded Research and Development Center that has a mission focused on delivering breakthrough science and technology in nuclear physics.
DOE expects to award the contract before the current agreement with Jefferson Science Associates, LLC expires on May 31, 2025, allowing for an anticipated three-month transition. DOE expects the selected contractor to assume full responsibility for the operation of TJNAF on June 1, 2025.
Interested parties have until September 30, 2024, to submit proposals. DOE will host a virtual pre-proposal conference on July 18, 2024, to discuss the salient elements of the RFP. DOE will also host a site tour for those interested on July 23, 2024. Registration information for both events is available on the competition website.
DOE’s Office of Science is responsible for the stewardship of TJNAF. The Office of Science is the largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit the Office of Science’s website.
The RFP is available on the TJNAF competition website.
END
U.S. Department of Energy issues request for proposals for contractor to manage and operate Thomas Jefferson National Accelerator Facility
TJNAF is a DOE national laboratory and DOE-sponsored Federally Funded Research and Development Center that has a mission focused on delivering breakthrough science and technology in nuclear physics
2024-07-03
ELSE PRESS RELEASES FROM THIS DATE:
Survivorship standards help address the distinct needs of adult cancer survivors
2024-07-03
Key Takeaways
More people are surviving cancer than ever before and living longer. This growing population of adult cancer survivors requires distinct survivorship services focused on long-term well-being.
Survey study demonstrates the value of American College of Surgeons’ survivorship accreditation standards, though specialized services in fertility and sexual health are less accessible.
CHICAGO — With the number of adult cancer survivors in the United States expected to reach 23 million by 2032,* the long-term needs of this ...
Mighty floods of the Nile River during warmer and wetter climates
2024-07-03
Summary
Global warming as well as recent droughts and floods threaten large populations along the Nile Valley. Understanding how such a large river will respond to an invigorated hydrological cycle is therefore a pressing issue. Insights can be gained by studying past periods with wetter and warmer conditions, such as the North African Humid Period eleven to six thousand years ago. A research team of the German Research Centre for Geosciences GFZ, led by Cécile Blanchet, together with colleagues ...
Popular prescription weight loss drugs linked to uncommon blinding condition
2024-07-03
A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION than similar patients who had not been prescribed these drugs.
Notably, the study found people with diabetes who had been prescribed semaglutide by their physician and then filled the prescription were more than four times more likely to be diagnosed with NAION. Those who were overweight or had obesity and prescribed this drug were more than seven times more likely to get the diagnosis.
The study, which ...
COVID-19 vaccination and parent-reported symptomatic child asthma prevalence
2024-07-03
About The Study: Researchers found that higher COVID-19 vaccination rates may confer protection against symptomatic asthma in children. COVID-19 vaccination yields prophylactic benefits against SARS-CoV-2 infection for individual children and may also protect against other human coronaviruses through cross-reactive antibody responses.
Corresponding Author: To contact the corresponding author, Matthew M. Davis, M.D., M.A.P.P., email matthew.davis@nemours.org.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.19979)
Editor’s ...
Experimental drug supercharges medicine that reverses opioid overdose
2024-07-03
The ongoing opioid epidemic in the U.S. kills tens of thousands of people every year. Naloxone, sold under the brand name Narcan, has saved countless lives by reversing opioid overdoses. But new and more powerful opioids keep appearing, and first responders are finding it increasingly difficult to revive people who overdose.
Now, researchers have found an approach that could extend naloxone’s lifesaving power, even in the face of ever-more-dangerous opioids. A team of researchers from Washington University School of Medicine in St. Louis, Stanford University and the University of Florida have identified potential ...
Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide
2024-07-03
About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was an observational study, future study is required to assess causality.
Corresponding Author: To contact the corresponding author, Joseph F. Rizzo III, M.D., email joseph_rizzo@meei.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2024.2296)
Editor’s Note: Please see the article for additional information, ...
Environmental toxicant exposure and depressive symptoms
2024-07-03
About The Study: The results of this study suggest that many common environmental toxicants are associated with depressive symptoms. This research provides insight into selecting environmental targets for mechanistic research into the causes of depression and facilitating efforts to reduce environmental exposures.
Corresponding Author: To contact the corresponding author, Jing Li, Ph.D., email jing.li@hsc.pku.edu.cn.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.20259)
Editor’s ...
Web-based cognitive behavioral treatment for bulimia nervosa
2024-07-03
About The Study: In this randomized clinical trial, a web-based cognitive behavioral self-help intervention effectively decreased eating disorder symptoms and illness-related burden in individuals with bulimia nervosa, underlining the potential of digital interventions to complement established treatments.
Corresponding Author: To contact the corresponding author, Steffen Hartmann, M.S., email steffen.hartmann@psychologie.uni-heidelberg.de.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.19019)
Editor’s ...
States with highest COVID-19 vaccination rates showed steepest decline in pediatric asthma prevalence
2024-07-03
States with Highest COVID-19 Vaccination Rates Showed Steepest Decline in Pediatric Asthma Prevalence
Study suggests COVID-19 vaccination might have broader benefits for children living with asthma
WILMINGTON, Del. (July 3, 2024) — States with high rates of COVID-19 vaccination saw more pediatric asthma patients get a break from their symptoms, according to new research published today in JAMA Network Open by leaders from Nemours Children’s Health and Endeavor Health.
“Asthma is one of the most common chronic illnesses among children in the United States, with about 4.7 million ...
Scientists unravel life-saving effect of dexamethasone in COVID-19
2024-07-03
Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité – Universitätsmedizin Berlin have now discovered how the cortisone compound influences the impaired inflammatory response and which patients benefit from it. Their method uses so-called single-cell analyses and raises hopes for a precise prediction tool for other therapies and diseases as well. The findings have been published in the scientific journal Cell.
It has long been puzzling why certain drugs work so well for some people and fail ...
LAST 30 PRESS RELEASES:
ODS FeCrAl alloys endure liquid metal flow at 600 °C resembling a fusion blanket environment
A genetic key to understanding mitochondrial DNA depletion syndrome
The future of edge AI: Dye-sensitized solar cell-based synaptic device
Bats’ amazing plan B for when they can’t hear
Common thyroid medicine linked to bone loss
Vaping causes immediate effects on vascular function
A new clock to structure sleep
Study reveals new way to unlock blood-brain barrier, potentially opening doors to treat brain and nerve diseases
Viking colonizers of Iceland and nearby Faroe Islands had very different origins, study finds
One in 20 people in Canada skip doses, don’t fill prescriptions because of cost
Wildlife monitoring technologies used to intimidate and spy on women, study finds
Around 450,000 children disadvantaged by lack of school support for color blindness
Reality check: making indoor smartphone-based augmented reality work
Overthinking what you said? It’s your ‘lizard brain’ talking to newer, advanced parts of your brain
Black men — including transit workers — are targets for aggression on public transportation, study shows
Troubling spike in severe pregnancy-related complications for all ages in Illinois
Alcohol use identified by UTHealth Houston researchers as most common predictor of escalated cannabis vaping among youths in Texas
Need a landing pad for helicopter parenting? Frame tasks as learning
New MUSC Hollings Cancer Center research shows how Golgi stress affects T-cells' tumor-fighting ability
#16to365: New resources for year-round activism to end gender-based violence and strengthen bodily autonomy for all
Earliest fish-trapping facility in Central America discovered in Maya lowlands
São Paulo to host School on Disordered Systems
New insights into sleep uncover key mechanisms related to cognitive function
USC announces strategic collaboration with Autobahn Labs to accelerate drug discovery
Detroit health professionals urge the community to act and address the dangers of antimicrobial resistance
3D-printing advance mitigates three defects simultaneously for failure-free metal parts
Ancient hot water on Mars points to habitable past: Curtin study
In Patagonia, more snow could protect glaciers from melt — but only if we curb greenhouse gas emissions soon
Simplicity is key to understanding and achieving goals
Caste differentiation in ants
[Press-News.org] U.S. Department of Energy issues request for proposals for contractor to manage and operate Thomas Jefferson National Accelerator FacilityTJNAF is a DOE national laboratory and DOE-sponsored Federally Funded Research and Development Center that has a mission focused on delivering breakthrough science and technology in nuclear physics